A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease

Ito Hidefumi0 个研究点目标入组 120 人开始时间: 2019年3月6日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Those who are at age between 55 and 79 years.
•(2) The patients should be within 3 years after the onset of motor symptoms.
•(3) The patients should be treated with levodopa/DCI within 3 months and with levodopa/DCI exclusively 28 days right before starting the trial.
•(4) The dose of levodopa/DCI should be taken from 150mg/day to 300mg/day.
•(5) The participant's score of MMSE should be 25 or higher.
•(6) The patient should be judged by attendant doctor to be appropriate for registration.
•(7) The agreement with the study should be obtained by the document.

•(1) Those who had been treated with the anti-parkinsonian drugs except levodopa/DCI for more than 1month.
•(2) Those who are in pregnancy, or possible to be pregnant or those who are in the breast-feeding.
•(3) Those who have taken antidepressant and/or anti-psychotic drugs.
•(4) Those who have a history of stroke and cerebrovascular disorders.
•(5) Those who had a history of epilepsy or those who are in treatment of epilepsy.
•(6) Those who have a history of alcohol intoxication, or have the treatment for alcoholic abuse.
•(7) Those who have severe comorbidity (liver dysfunction, renal dysfunction and endocrinological disorders).
•(8) Those who have a familial history of Parkinson's disease.
•(9) Those who have a history of allergic reaction with 123I-ioflupane.

发起方

Ito Hidefumi